{"entity":{"id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","aka":[],"tldr":"A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.","summary":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP is a phase 2 interventional study registered as NCT07354074 by Novartis Pharmaceuticals, with 50 participants planned, started 2026-04-28 and due to reach its primary completion in 2033-02-23. Interventions recorded: Asciminib single agent.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07354074","url":"https://clinicaltrials.gov/study/NCT07354074"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["asciminib"],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07354074","phase":"2","setting":"A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation","sponsor":"Novartis Pharmaceuticals","enrolled":50,"outcomes":[]},"route":"/trials/nct07354074/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}